pharma · Chronic Obstructive Pulmonary Disease (COPD) · Non-Small Cell Lung Cancer
AstraZeneca
AstraZeneca AB
NovaPharmaNews editorial coverage mentioning AstraZeneca — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridgeshire CB2 0AA, GB
- Employees
- 79,242
- Programs
- 249
- Drugs
- 238
- Patents
- 2
News & analysis
NovaPharmaNews articles mentioning AstraZeneca — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning AstraZeneca — regulatory, clinical, and market analysis.
Datroway Priority Review Fuels Hope for Metastatic Triple-Negative Breast Cancer Patients
The FDA has granted Priority Review to Datroway for the treatment of metastatic triple-negative breast cancer (TNBC) in patients not eligible for immunotherapy. This designation marks a significant step for AstraZeneca and offers a potential new therapeutic avenue for a challenging cancer subtype.
FDA Approves Baxdrostat (Baxfendy) as First Aldosterone Synthase Inhibitor for Uncontrolled Hypertension
The FDA has approved AstraZeneca's baxdrostat (Baxfendy), the first-in-class aldosterone synthase inhibitor, for adults with uncontrolled hypertension. This landmark approval offers a new therapeutic option for patients with difficult-to-treat hypertension.
ASCO 2026: European Pharma's Quiet Showing and What AstraZeneca & Roche Must Address
The ASCO 2026 annual meeting presented a subdued landscape for European pharmaceutical giants like AstraZeneca and Roche, highlighting areas where both companies need to intensify their strategic efforts. Despite a quiet conference, significant market dynamics are at play for these oncology leaders.
AstraZeneca's Imfinzi and Imjudo: A Breakthrough in Liver Cancer Treatment
AstraZeneca's Imfinzi and Imjudo have shown promising results in early-stage liver cancer at ASCO. This article explores the implications for the pharmaceutical industry.
FDA Delays AstraZeneca's Breast Cancer Drug Review: Key Insights
The FDA has delayed the review of AstraZeneca's breast cancer drug, raising questions about the future of the drug and its market impact. Here's what you need to know.
IMFINZI® Approved for High-Risk Bladder Cancer: A Game Changer
AstraZeneca's IMFINZI® (durvalumab) has received FDA approval as the first immunotherapy combination for BCG-naïve, high-risk non-muscle-invasive bladder cancer, marking a significant advancement in oncology treatment options.
Imfinzi Receives FDA Approval for Bladder Cancer Treatment
AstraZeneca's Imfinzi has been approved by the FDA for a new indication in bladder cancer treatment. This approval opens new avenues for investment and market competition.
AstraZeneca's Imfinzi Secures Second Bladder Cancer Approval
AstraZeneca's Imfinzi has gained a second approval for bladder cancer treatment, marking a significant milestone in its development. This article explores the implications for the pharmaceutical landscape.
FDA Delays Decision on AstraZeneca Breast Cancer Pill: What It Means
The FDA has postponed its decision on AstraZeneca's breast cancer pill, raising questions about the drug's future. This article explores the implications for the pharmaceutical industry.
AstraZeneca's Breast Cancer Pill and ADAP Deal Insights
This article covers AstraZeneca's latest breast cancer pill developments and an ADAP deal in Florida, highlighting key implications for the pharmaceutical industry.
FDA Delays Ruling on AstraZeneca’s Breast Cancer Drug: Implications for Pharma
The FDA's delay on AstraZeneca's breast cancer drug ruling raises significant questions for the pharmaceutical industry. This article explores the implications for investors and pharma teams.
FDA Approval for Datroway: Implications for Breast Cancer Treatment
The FDA has granted approval for Datroway, a significant development for breast cancer treatment by Daiichi Sankyo and AstraZeneca. This article explores the implications for investors and pharma teams.